XML 21 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated statements of operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Net revenues $ 537,840 $ 535,031 $ 494,366
Cost of revenues 114,867 114,877 106,501
Gross profit 422,973 420,154 387,865
Operating costs and expenses:      
Research, development and clinical studies 206,085 201,303 132,010
Sales and marketing 173,658 137,057 118,017
General and administrative 132,753 126,127 107,437
Total operating costs and expenses 512,496 464,487 357,464
Operating income (loss) (89,523) (44,333) 30,401
Financial (expenses) income, net 7,677 (7,742) (12,299)
Income (loss) before income taxes (81,846) (52,075) 18,102
Income tax 10,688 6,276 (1,706)
Net income (loss) $ (92,534) $ (58,351) $ 19,808
Basic net income (loss) per ordinary share (in usd per share) $ (0.88) $ (0.56) $ 0.20
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) 104,660,476 103,433,274 100,930,866
Diluted net income (loss) per ordinary share (in usd per share) $ (0.88) $ (0.56) $ 0.18
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) 104,660,476 103,433,274 108,877,648